The new Eurosurveillance website is almost here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2017: Volume 22/ Issue 19 Article 1
Back to Table of Contents
Download (pdf)

Eurosurveillance, Volume 22, Issue 19, 11 May 2017
Rapid communication
Zhu, Zhou, Li, Yang, Li, Huang, Zou, Chen, Wei, Tang, Liu, Dong, Wang, and Shu: Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017

+ Author affiliations

Citation style for this article: Zhu W, Zhou J, Li Z, Yang L, Li X, Huang W, Zou S, Chen W, Wei H, Tang J, Liu L, Dong J, Wang D, Shu Y. Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017. Euro Surveill. 2017;22(19):pii=30533. DOI:

Received:14 April 2017; Accepted:10 May 2017

Five outbreak waves have occurred since the low-pathogenic avian influenza A(H7N9) virus (LPAI H7N9) first emerged in spring 2013 in eastern China [1]. Highly pathogenic avian influenza A(H7N9) (HPAI H7N9) viruses, derived from their LPAI H7N9 counterparts, have recently been isolated from humans and resulted in fatal outcome in Guangdong, China (A/Guangdong/17SF003/2016 (SF003) and A/Guangdong/17SF006/2017 (SF006)) [2]. Both viruses contain an insertion of four amino acids (KRTA) in the haemagglutinin (HA) proteolytic cleavage site, indicating their pathotype switch from LPAI to HPAI. Furthermore, they retain a series of genetic features contributing to the ability to infect humans (e.g. 186V in the HA protein (H3 numbering) and 627K in the PB2 protein) that raise concerns regarding their pandemic potential. Amino acid substitutions associated with resistance to neuraminidase inhibitors (NAIs) have been detected in both SF003 and SF006 viruses. Therefore, to update public health risk assessment, we investigated trypsin-dependent infectivity, receptor binding properties, antigenic alternations of the HPAI H7N9 viruses, as well as their sensitivity to antiviral drugs. All LPAI H7N9 viruses in this study were isolated from humans.

Similar replication ability of HPAI H7N9 viruses with or without trypsin

Avian influenza viruses with multiple basic amino acids at the HA cleavage site are able to replicate in cell culture in the absence of N-p-tosyl-L-phenylalanine chloromethyl ketone-treated (TPCK) trypsin [3]. We therefore examined the in vitro growth of SF003 and SF006 in MDCK cells in the presence or absence of TPCK trypsin. Cells were fixed with ice-cold 4% paraformaldehyde complemented with Triton X-100 and detected by staining of the nucleoprotein (NP). LPAI H7N9 virus (A/Anhui/1/2013 (AnH1)) and HPAI H5N6 virus (A/Guangdong/99710/2014 (GD710)) were included as control. The three HPAI viruses (GD710, SF003 and SF006) had comparable ability to replicate both in the presence and absence of TPCK trypsin, while the LPAI H7N9 AnH1 virus failed to replicate in the absence of TPCK trypsin (Figure 1).

Figure 1

Replication of highly pathogenic avian influenza A(H7N9) viruses from humans in MDCK cells with or without TPCK trypsin, China, 2016­–2017 (n = 2)


AnH1: A/Anhui/1/2013 (LPAI H7N9); GD710: A/Guangdong/99710/2014 (HPAI H5N6); MDCK: Madin-Darby canine kidney epithelium; PBS: phosphate-buffered saline; SF003: A/Guangdong/17SF003/2016 (HPAI H7N9); SF006: A/Guangdong/17SF006/2017 (HPAI H7N9); TPCK: N-p-tosyl-L-phenylalanine chloromethyl ketone-treated.

Serial viral dilutions of 10−3, 10−4, 10−5, 10−6 and 10−7 TCID50 were inoculated on MDCK cells. Mock cells were inoculated with PBS.

Dual receptor-binding profile of HPAI H7N9 viruses

HA amino acids 226L/I and 186V have been reported to contribute to the dual receptor binding properties of the LPAI H7N9 viruses [4,5]. However, 226L has mutated back to 226Q in the HPAI H7N9 viruses. In order to verify whether the receptor-binding profile of HPAI H7N9 differed from the LPAI viruses, we conducted a binding assay with synthetic sialylglycopolymers. The sialylglycopolymers, including 3’-SLN, 3’-SLN-LN, 6’-SLN and 6’SLN-LN (LN corresponds to lactosamine (Galβ1–4GlcNAc) and 3’SLN and 6’SLN, respectively, correspond to Neu5Ac α2,3 and Neu5Ac α2,6 linked to LN), were obtained from the Consortium of Functional Glycomics ( As described previously [6,7], 32 haemagglutinating units (HAU) of live virus per well were used in the ELISA test. Binding was detected by a human chimeric anti-H7 monoclonal antibody (MoAb) or mouse-derived anti-N9 MoAb. The optical density was read at 450/630 nm. As shown in Figure 2, the LPAI H7N9 AnH1 virus bound to sialic acid α2,3 and α2,6 receptors, as expected. The HPAI H7N9 viruses SF003 and SF006 showed typical dual receptor preference, with increased affinity to α2,3 receptors compared with the LPAI H7N9 AnH1 virus. When using the anti-N9 monoclonal antibody, SF006 virus showed a slightly enhanced binding preference for α2,6 receptors compared with the AnH1 virus (Figure 2C). This phenotype may be due to the binding of N9 to the human-type receptor as reported recently [8].

Figure 2

Direct glycan receptor binding of highly pathogenic avian influenza A(H7N9) viruses from humans, China, 2016–2017 (n =2)


AnH1: A/Anhui/1/2013 (LPAI H7N9); LN: lactosamine (Galβ1–4GlcNAc); OD: optical density; SF003: A/Guangdong/17SF003/2016 (HPAI H7N9); SF006: A/Guangdong/17SF006/2017 (HPAI H7N9); 3’SLN: Neu5Acα2–3 linked to LN; 6’SLN: Neu5Acα2–6 linked to LN.

Each sample was tested in duplicate. Absorbance was read at 450 nm. Binding profiles of tested viruses are presented with glycans of 0, 0.625, 1.25, 2.5, 5 and 10 μg/mL.

Divergent antigenic properties of HPAI relative to LPAI H7N9 viruses

Compared with the sequences of LPAI H7N9 viruses, several substitutions, including I38T, S112P, K164E and I317V (H7 numbering) have occurred in the HA1 protein of HPAI H7N9 viruses. To investigate the antigenic difference among HPAI and LPAI H7N9 viruses, a haemagglutination inhibition (HI) assay was conducted using the ferret anti-sera against A/Anhui/1/2013 (wildtype), A/Anhui/1/2013 (reverse genetics) and A/Shanghai/2/2013 (wildtype) according to standard protocols [9] (Table 1). Antigenic analysis demonstrated that all LPAI H7N9 viruses except A/Hunan/06948/2017 and A/Anhui/60933/2016 reacted well with ferret antiserum of H7N9 vaccine strains AnH1 (either wild-type or reverse genetics strains) or A/Shanghai/2/2013 (Table 1). However, both HPAI H7N9 viruses (SF003 and SF006) showed low or no reactivity to antisera of LPAI H7N9 vaccine strains.

Table 1

Haemagglutination inhibition reactions of human influenza A(H7N9) virus isolates, China, 2016–2017 (n = 16)

Strains          HA          Titre of ferret antiserum to antigen
AnH1 AnH1-RG SH2
A/Anhui/1/2013 256 160 80 320
A/Anhui/1/2013-RG 256 320 160 640
A/Shanghai/2/2013 128 320 160 640
A/Shanghai/2/2013-RG 64 320 160 640
A/Fujian/02152/2017 1,024 160 40 160
A/Anhui/60936/2016 1,024 80 40 80
A/Jiangsu/06463/2017 1,024 320 80 160
A/Jiangsu/06454/2017 128 80 40 160
A/Jiangsu/60466/2016 32 160 40 80
A/Fujian/54840/2016 2,048 160 40 160
A/Jiangsu/60460/2016 2,048 80 40 80
A/Hunan/02287/2017 512 160 40 80
A/Guangdong/60060/2016 512 320 160 640
A/Guangdong/17SF004/2017 2,048 320 160 640
A/Guangdong/60923/2016 32 320 80 320
A/Guangdong/60061/2016 2,048 160 80 320
A/Hunan/06948/2017 2,048 40 < 40 80
A/Anhui/60933/2016 32 < 40 < 40 < 40
A/Guangdong/17SF003/2016 256 < 40 < 40 < 40
A/Guangdong/17SF006/2017 512 40 < 40 40

AnH1: A/Anhui/1/2013; HA: haemagglutinin; RG: reverse genetic; SH2: A/Shanghai/2/2013.

Homologous titres are indicated in bold.

Multiple drug resistance of HPAI H7N9 viruses containing the R292K substitution

The substitution R292K (N2 numbering), which is associated with reduced susceptibility to NAIs [4], has been reported in the HPAI H7N9 viruses. Considering the possible effect that quasispecies containing NA-292R/K may have on drug susceptibility, we first purified SF003 virus from plaques. Two virus clones with either amino acid 292K or 292R in the NA protein, were analysed in a neuraminidase inhibition assay [10]. The susceptibility of the viruses was categorised by the criteria recommended by the World Health Organization (WHO) Antiviral Working Group [11]. As expected, the influenza A(H3N2) wild-type virus (A/Beijing-Haidian/1942/2014) and the LPAI H7N9 wild-type virus (AnH1) were sensitive to the three NAIs, while the A/Texas/12/2007 virus which contained the E119V substitution in the NA protein showed highly reduced inhibition to oseltamivir (mean: 798-fold increase in IC50) but normal inhibition to zanamivir and peramivir (Table 2). The HPAI H7N9 virus SF003 with NA-292R was similar to AnH1 and sensitive to all the three NAIs. However, the substitution R292K in the NA protein induced a mean 53,855-fold increase in the IC50 of oseltamivir, and a 3,556-fold and 73-fold increase in peramivir and zanamivir, respectively.

Table 2

Susceptibility of human isolates of highly pathogenic avian influenza A(H7N9) viruses to neuraminidase inhibitors, China, 2016 (n =2)

Viruses Oseltamivir Zanamivir Peramivir
Mean IC50 (nM) ± SD Fold changea Mean IC50 (nM) ± SD Fold changeb Mean IC50 (nM) ± SD Fold changea
A/Anhui/1/2014 (H7N9) 0.58 ± 1.03 1.0 0.66 ± 1.07 1.0 0.05 ± 1.02 1.0
A/Guangdong/17SF003/2016 (H7N9–292R) b 0.84 ± 1.06 1.4 0.95 ± 1.12 1.4 0.07 ± 1.04 1.4
A/Guangdong/17SF003/2016 (H7N9–292K) b 31236.00 ± 1.68 53,855.2 69.33 ± 1.10 73.0 248.90 ± 1.18 3,555.7
A/Beijing-Haidian/1942/2014 (H3N2) 0.12 ± 1.14 1.0 0.12 ± 1.09 1.0 0.06 ± 1.04 1.0
A/Texas/12/2007 (H3N2-E119V) b 95.70 ± 1.07 797.5 0.93 ± 1.10 7.75 0.10 ± 1.06 1.7

HPAI: highly pathogenic avian influenza; IC50: 50% inhibitory concentration; SD: standard deviation.

a Compared with that of wild-type viruses. A/Texas/12/2007 (H3N2-E119V) and A/Anhui/1/2014 (H7N9) were the wild-type influenza A(H3N2) and influenza A(H7N9) viruses, respectively.

b N2 numbering.


Compared with other avian influenza viruses, LPAI H7N9 and HPAI H5N1 are of most concern because of their high mortality and morbidity. LPAI H7N9 poses a higher risk for humans than HPAI H5N1 because LPAI H7N9 could bind sialic acid α2,6 human-type receptors while HPAI H5N1 could not. Our data show that the HPAI H7N9 viruses retained dual receptor binding properties, with slightly increased binding preference for both receptors compared with LPAI H7N9 (AnH1) viruses. It is well known that human upper respiratory tissues and trachea contain mainly α2,6 receptors while lung tissue possesses mixtures of avian type α2,3 and human type α2,6 receptors [7,12]. The persisting preference for both avian- and human-type receptors of HPAI H7N9 viruses may result in their circulation in poultry and possible transmission among humans.

Vaccination is the primary measure to control the spread of influenza virus infection in humans. Previously, WHO recommended A/Anhui/1/2013 (LPAI H7N9) as the vaccine strain for influenza A(H7N9) virus. However, our data show that the newly emerged HPAI H7N9 viruses did not react strongly with the ferret antisera of LPAI H7N9 viruses. Therefore, WHO has recently recommended SF003 as an additional candidate vaccine virus.

Among the four commercially available NAIs, oseltamivir and zanamivir are the predominant NAIs for influenza prophylaxis and treatment [13]. Our results show that HPAI H7N9 viruses with the 292K amino acid in the NA protein exhibited multi-drug resistance. The viral neuraminidase could acquire the R292K substitution as early as 2 days after administration of the antiviral drug. Further assessment of the fitness of drug-resistant viruses is urgently needed.

In summary, although the highly pathogenic influenza A(H7N9) virus was thought to cause higher risk in poultry than the low-pathogenic virus, our study, especially regarding the receptor profile of HPAI H7N9 viruses, has implications on surveillance and control strategies not only in the animal sector but also for public health. Our study also highlighted the critical role of antiviral surveillance monitoring in the clinical management of influenza virus infection as an essential component of pandemic preparedness.


This study was supported by the National Mega-projects for Infectious Diseases (2014ZX10004002 to YS) and the National Key Research and Development Program of China (2016YFC1200200 to YS and 2016YFD0500208 to DW). The contents of this article are solely the responsibility of the authors and do not necessarily represent the views of China CDC or other organisations.

Conflict of interest

None declared.

Authors’ contributions

YS and DW designed the study. JZ, ZL, XL, WH, SZ, WC, HW, JT, LL and JD performed the study. WZ analysed the data and drafted the manuscript. WFZ, JFZ, LY and YS revised the manuscript.


  1. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W,  et al.  Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888-97.PMID: 23577628

  2. World Health Organization (WHO). Human infection with avian influenza A(H7N9) virus – China. Disease outbreak news. Geneva: WHO; 2017. Available from:

  3. World Organisation for Animal Health (OIE). Manual of diagnostic tests and vaccines for terrestrial animals. Chapter 2.3.4. Avian influenza (infection with avian influenza viruses). Paris: OIE; [Accessed: 2 May 2017]. Available from:

  4. Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X,  et al.  Biological features of novel avian influenza A (H7N9) virus. Nature. 2013;499(7459):500-3. DOI: 10.1038/nature12379 PMID: 23823727

  5. Shi Y, Zhang W, Wang F, Qi J, Wu Y, Song H,  et al.  Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science. 2013;342(6155):243-7. DOI: 10.1126/science.1242917 PMID: 24009358

  6. Childs RA, Palma AS, Wharton S, Matrosovich T, Liu Y, Chai W,  et al.  Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol. 2009;27(9):797-9. DOI: 10.1038/nbt0909-797 PMID: 19741625

  7. Chandrasekaran A, Srinivasan A, Raman R, Viswanathan K, Raguram S, Tumpey TM,  et al.  Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008;26(1):107-13. DOI: 10.1038/nbt1375 PMID: 18176555

  8. Benton DJ, Wharton SA, Martin SR, McCauley JW. Role of Neuraminidase in Influenza A(H7N9) Receptor Binding. J Virol. 2017;JVI.02293-16. DOI: 10.1128/JVI.02293-16 PMID: 28356530

  9. World Health Organization (WHO) Collaborating Centers from Reference and Research on Influenza. Concepts and procedures for laboratory-based influenza surveillance / prepared by the WHO Collaborating Centers for Reference and Research on Influenza. 1982: Washington DC: United States Department of Health and Human Services. p. pB17-35.

  10. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.Antimicrob Agents Chemother. 2009;53(10):4433-40. DOI: 10.1128/AAC.00334-09 PMID: 19651908

  11. Okomo-Adhiambo M, Nguyen HT, Abd Elal A, Sleeman K, Fry AM, Gubareva LV. Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria.Influenza Other Respi Viruses. 2014;8(2):258-65. DOI: 10.1111/irv.12215 PMID: 24299049

  12. Walther T, Karamanska R, Chan RW, Chan MC, Jia N, Air G,  et al.  Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. PLoS Pathog. 2013;9(3):e1003223. DOI: 10.1371/journal.ppat.1003223 PMID: 23516363

  13. Webster RG, Govorkova EA. Continuing challenges in influenza.Ann N Y Acad Sci. 2014;1323(1):115-39. DOI: 10.1111/nyas.12462 PMID: 24891213

Back to Table of Contents
Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.